• Şevket Barış Morkavuk, Murat Güner, Serdar Çulcu, Aydan Eroğlu, Sancar Bayar, and Ali Ekrem Ünal.
• Department of Surgical Oncology, Ankara City Hospital, Ankara, Turkey.
• Int. J. Clin. Pract. 2021 Apr 1; 75 (4): e13897.

PurposeThe aim of this study is to evaluate the relation between LVI and molecular subtypes in invasive breast cancers and to find out whether LVI which is a histopathologic indicator has a role in subtype classification or not.MethodsOne hundred and seventy-six patients who had mastectomy for breast cancer between 2013 and 2018 in the Department of Surgical Oncology, Faculty of Medicine, Ankara University were retrospectively analysed. One hundred and thirty-two patients who had LVI, ER, PR, Her 2 and Ki-67 index status information provided in their pathology results were included in the study. The relationship between molecular subtypes and LVI was investigated.ResultsOne hundred and thirty-two patients were analysed retrospectively. Eighty-two patients had LVI and 50 patients had not. We found a relationship between Luminal B with Her2(-) and LVI, basal like and LVI (P = .00). No significant statistical difference was found between LVI and other molecular subtypes. We confirmed these results with multiple variable analysis (%77.3 correlation).ConclusionsAs a result, we found that LVI can affect molecular subtypes. This showed that a histopathological factor may affect tumour biology. In other words, breast cancer is a heterogeneous disease with many different predictors and prognostic variables.© 2020 John Wiley & Sons Ltd.

11 keywords...

hide…